 IRVINE, Calif. BASEL, Switzerland--BUSINESS WIRE--Urovant Sciences Nasdaq: UROV announced today that the U.S. Food and Drug Administration FDA has approved the New Drug Application NDA for once-daily 75 mg GEMTESA vibegron, a beta-3 adrenergic receptor β3 agonist, for the treatment of overactive bladder OAB with symptoms of urge urinary incontinence UUI, urgency, and urinary frequency in adults. This approval marks the first new oral branded OAB medication approved by the FDA 